PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Sabatine, Marc S.
TI  - Otamixaban May Reduce the Risk of Ischemic Events in Patients with NSTE-ACS
DP  - 2009 Dec 01
TA  - MD Conference Express
PG  - 20--20
VI  - 9
IP  - 4
4099  - http://mdc.sagepub.com/content/9/4/20.1.short
4100  - http://mdc.sagepub.com/content/9/4/20.1.full
AB  - Results from the phase 2 Study Program to Evaluate the Prevention of Ischemia with Direct Xa inhibition [SEPIA-ACS1 TIMI 42; NCT00317395] study provided promising data that otamixaban, an intravenous direct Factor Xa inhibitor, at intermediate doses may be associated with a lower risk of ischemic events with similar bleeding compared with the current standard of care in patients with non-ST elevation acute coronary syndromes (NSTE-ACS) [Sabatine MS et al. Lancet 2009].